Final analysis of the phase III LITESPARK-005 study of belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC)

Basit Öğe Kaydı
dc.contributor.authorRini, B. I.
dc.contributor.authorRodriguez, C. Suarez
dc.contributor.authorAlbiges, L.
dc.contributor.authorJalkanen, K.
dc.contributor.authorOria, G. A. De Velasco
dc.contributor.authorBurotto, M.
dc.contributor.authorGhatalia, P.
dc.date.accessioned2025-11-16T19:33:36Z
dc.date.issued2024
dc.departmentİstanbul Medeniyet Üniversitesi
dc.descriptionAnnual Congress of the European-Society-for-Medical-Oncology (ESMO) -- SEP 13-17, 2024 -- Barcelona, SPAIN
dc.description.abstract[Abstract Not Available]
dc.description.sponsorshipMerck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA
dc.description.sponsorshipMerck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
dc.description.sponsorshipEuropean Soc Med Oncol
dc.identifier.doi10.1016/j.annonc.2024.08.2317
dc.identifier.endpage1263
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.startpage1262
dc.identifier.urihttps://doi.org/10.1016/j.annonc.2024.08.2317
dc.identifier.urihttps://hdl.handle.net/20.500.14730/15096
dc.identifier.volume35
dc.identifier.wosWOS:001326612903084
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofAnnals of Oncology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.titleFinal analysis of the phase III LITESPARK-005 study of belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC)
dc.typeConference Object

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu